Xenon Pharmaceuticals (NASDAQ:XENE) Releases Earnings Results, Meets Expectations

Xenon Pharmaceuticals (NASDAQ:XENE) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($1.17), Zacks reports. During the same period in the prior year, the firm posted ($0.83) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Xenon’s Phase III X-TOLE2 for azetukalner (AZK) exceeded expectations with strong efficacy and tolerability, and the company plans an NDA submission in Q3 2026 with an anticipated U.S. launch in late 2027/early 2028 (standard FDA review + DEA scheduling).
• Long-term open-label data are compelling — ?48-month patients showed a 91% median reduction in monthly focal seizures and ~40% were seizure-free for ?12 months, supporting AZK’s potential differentiation and durable benefit.
• Xenon is expanding AZK’s opportunity beyond focal epilepsy — EXACT (primary generalized tonic?clonic seizures) is enrolling and three Phase III depression studies (X?NOVA 2 readout expected H1 2027) could materially broaden the addressable market if successful.
• Early-stage pain programs XEN1701 (NaV1.7) and XEN1120 (KV7) are completing first?in?human studies this year with plans to advance to Phase II acute pain POC trials, but these are early-stage and carry typical development risk.
• Financially strong after a $747.5M offering, Xenon ended Q1 with about $1.3 billion in cash and equivalents, which management says funds operations into 2029 and supports launch and pipeline advancement.

Xenon Pharmaceuticals Stock Down 4.4%

Shares of NASDAQ XENE traded down $2.59 during mid-day trading on Thursday, reaching $56.00. 576,359 shares of the company were exchanged, compared to its average volume of 917,107. The stock has a market cap of $5.41 billion, a price-to-earnings ratio of -12.84 and a beta of 0.65. Xenon Pharmaceuticals has a 1 year low of $28.19 and a 1 year high of $63.95. The firm has a 50-day moving average of $54.64 and a 200 day moving average of $46.62.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on XENE shares. Wedbush lowered their target price on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Monday, March 16th. HC Wainwright lifted their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Robert W. Baird increased their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th. Morgan Stanley set a $97.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Jefferies Financial Group set a $100.00 price target on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and an average target price of $73.13.

Insider Buying and Selling at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 270,000 shares of the firm’s stock in a transaction dated Monday, March 9th. The shares were sold at an average price of $60.33, for a total value of $16,289,100.00. Following the sale, the chief executive officer directly owned 6,000 shares in the company, valued at approximately $361,980. This trade represents a 97.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Andrea Difabio sold 2,607 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total transaction of $156,706.77. Following the completion of the transaction, the insider directly owned 4,893 shares in the company, valued at approximately $294,118.23. The trade was a 34.76% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 296,707 shares of company stock worth $17,845,365 over the last quarter. Insiders own 4.07% of the company’s stock.

Institutional Investors Weigh In On Xenon Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of Xenon Pharmaceuticals in the 4th quarter worth $33,000. Danske Bank A S purchased a new position in Xenon Pharmaceuticals in the 3rd quarter worth $32,000. Caitong International Asset Management Co. Ltd acquired a new stake in Xenon Pharmaceuticals during the 4th quarter worth about $43,000. Osaic Holdings Inc. lifted its position in Xenon Pharmaceuticals by 541.4% during the 2nd quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the period. Finally, State of Wyoming grew its stake in Xenon Pharmaceuticals by 30.4% during the 4th quarter. State of Wyoming now owns 1,501 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 350 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.